Turning Point and Zai Lab Broaden Collaboration
11. Januar 2021 06:45 ET
|
Zai Lab Limited; Turning Point Therapeutics, Inc.
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point’s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to Receive $25 Million Upfront, with Up to Approximately...